Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Non-small cell lung cancer (NSCLC) is the most deadly cancer in the world. NSCLC annually causes 150,000 deaths in the US and greater than 1 million worldwide. The standard treatment for early stage NSCLC is lobectomy with lymphadenectomy. However, many patients are poor operative candidates or decline surgery. An emerging alternative is Stereotactic Body Radiation Therapy (SBRT). Mounting evidence from Phase I/II studies demonstrates that SBRT offers excellent local control. Most SBRT trials focused on small, peripheral tumors in inoperable patients. Increasingly, clinical trials study SBRT in operable patients, often with larger, central tumors. Using clinical staging, a significant proportion of patients harbor occult nodal metastases when undergoing SBRT to the primary tumor alone. Subgroups of patients carry even higher risk of nodal metastases. These nodal metastases frequently would be removed by surgical intervention. However, SBRT, at present, is only directed at the primary tumor, potentially leading to regional failures in otherwise curable patients. To increase the effectiveness of SBRT for lung tumors, the next logical step is to explore whether the highest risk areas of disease spread can be identified and targeted. Regional failure could be reduced and outcome improved in a significant proportion of patients treated with SBRT if the primary nodal drainage (PND) were identified, targeted and treated in addition to the primary tumor. We propose to conduct a study to determine how well water soluble iodinated contrast material when injected directly into the tumor can be visualized on CT scan and integrated into radiation therapy treatment planning.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Quynh-Thu Le, MD
- Joseph Shrager
- Maximilian Diehn, MD, PhD
- Heather Wakelee
- Ann Leung
- Daniel Sze, MD, PhD
- Lawrence "Rusty" Hofmann, MD
- Billy W. Loo, Jr., MD, PhD, DABR
- Nishita Kothary, MD
- device : True Beam
- device : Cyberknife
- device : Trilogy
- drug : Iohexol
- procedure : Stereotactic Body Radiation Therapy (SBRT)
- radiation : Computed Tomography (CT)
Ages Eligible For Study:
- Either 1. Established primary lung cancer/ cancer metastatic to lung, OR 2. Lesion suspicious for malignancy in lung, according to the following criteria: A. Histopathologically confirmed lung cancer or cancer metastatic to lung, OR B. Plan for biopsy of suspicious lung mass based on imaging (growth on serial CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR C. Known metastatic cancer, with metastases to the lung based on imaging - Age > 18 years old - Eastern Clinical Oncology Group performance status 0, 1 or 2 (Appendix IV) - No prior surgery, chemotherapy, or radiation for the current lung tumor - Both men and women and members of all races and ethnic groups are eligible for this trial.